<DOC>
	<DOC>NCT00385307</DOC>
	<brief_summary>To evaluate the efficacy of two fixed doses of SR58611A (175 mg q12 and 350 mg q12) compared to placebo in patients with Major Depressive Disorder (MDD) using paroxetine (20 mg qd) as positive control. In addition, the tolerability and safety of SR58611A in patients with MDD will be evaluated.</brief_summary>
	<brief_title>Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<criteria>Patient with Major Depressive Disorder diagnosed according to Diagnostic and Statistical Manual of Mental Disorders DSMIVTR Patient meets criteria for a recurrent Major Depressive Episode (MDE) Patient meets severity assessments of depression specified by the study Patient is at immediate risk for suicidal behavior Patient is with a unstable medical condition Patient with psychotic features, catatonic features, seasonal pattern or postpartum onset Patient has taken concomitant treatment that may interfere with valid collection or interpretation of study data Patient has been treated with nonpharmacologic therapy intended to treat depression in the past 6 months Patient has been treated with paroxetine (Paxil) within the previous 6 months Patient is pregnant or breastfeeding, or likely to become pregnant during the course of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Depression</keyword>
	<keyword>Clinical Trials</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>